Category: Money Tips Date: 2006-05-25
Source: Donghai Securities Author: Wang Xingjun
Since 2004, the controlling shareholder Shanghai Industrial Holdings Limited has been approved through asset replacement Ershi Shangshiliange backdoor listing, the company will begin to gradually withdraw from the original wool business, and through holdings of the holding of the Shanghai Medical Instrument, Shanghai Cloud Lake medicine and other enterprises, the main business to the pharmaceutical industry in transition. By last July, Shangshilianhe tried through asset replacement method, the transferee's actual holdings, including Hangzhou Hu Qing Tong's medicine, the pharmaceutical companies in Xiamen, Liaoning, good nurses, medicine, and so four shares of pharmaceutical companies, despite the time limit is not due to able to complete the statutory procedure to temporarily put aside, but the company said it will actively promote this. Pharmaceutical stocks this year, the real reform period, controlling an injection of real profits on the ability of Hangzhou "youth treasure" of the shares. As a result, the real Department of Medicine plate integrated into the business to further focus on one, the real medicine, as the pharmaceutical industry on a solid platform for the Group under its command position more clearly uncertain, its future development direction of the core includes two major areas of medicine and biochemical.
Historical Information: G on the real joint (600,607): a serious oversold, with an excellent investment value of the July 15, 2006
Source: Northeast Securities Author: Zheng Li Ting
Recent market slump to the continuous loss of some investors. After a week of decline, the market has been effectively short the release of kinetic energy, but to do more warm slowly cohesion. Today, the turnover is like a sharp fall in the market rally triggered by a critical point, wave to oversold stocks as the main force of the stock market rebound began to hit. Since the surface of the oversold bounce technical requirements, then the fundamental premise of guaranteed to find short-term oversold stocks will be our main line of attack. After we repeated studies and screening, we believe that G on the real joint (600,607) have oversold Quotes of the leading quality, market outlook is expected to launch a wave of retaliatory rally.
Decentralized to centralized core profitability of emergent
Shanghai has set up overseas as the largest and most powerful comprehensive enterprise group, the company in recent years to gradually divest non-core businesses, to form a pharmaceutical, real estate, international trade into three main sections of leading enterprises. Re-acquisition of the company since 1997, has been dedicated to integration of asset structure, expanding profit margins, and actively cultivate the company leading industries, and improve core competitiveness. In particular, in 2000, the company successfully issued 50 million A share capital increase, and actively advance biomedical industry, and constantly reinforce the main business, through the substantive expansion of the company's asset size and business strength. 2004 Shanghai Industrial Holdings Limited completed the acquisition of 56.63% stake in the company, then in June 2005 with the company exchange of assets, will be held by four pharmaceutical companies into the full stake, making the company to become a medical specialty listed company, to enhance the company's market position, brand building and long-term profitability. At present, the company's main business, including biological and biochemical medicine, pharmaceutical, medical devices, etc., the company owned enterprises in Guangdong Tempe, Shenzhen and Hong Tai, Changzhou Pharmaceutical, Chifeng Mongin, Chifeng Ike, Shanghai and medical equipment. Meanwhile, the company also has subsidiaries involved in real estate business and Jieyou fragmented, so the real specially in the formation of the Group's real estate with a view to its operations placed under the unified management of all property, the future is expected to nurture the nation's largest real estate group.
"Xiamen in the pharmaceutical companies," such as the termination of the asset replacement does not affect the company's restructuring of the pharmaceutical industry
The exchange was forced to terminate the company's assets, but the company concerned said that it will not affect the transformation of G on the real joint strategic direction of the pharmaceutical industry, it will not affect the actual controller of Shanghai Industrial Holdings Limited on the company's support, G on the real - Alliance will continue the planning of the Group in accordance with the actual integration of medical resources within the group to undertake the important task of the Group of pharmaceutical industry platform. Shanghai Industrial Group as the pharmaceutical industry to develop one of the three major industries, after a decade of development, at present, has formed a nearly 21 billion investment, more than 1.5 billion of net assets in 2005 is expected to achieve more than 250 million of the profits. December 2005, the Group's corporate real independent research and development of anti-cancer bio-genetic drug recombinant human adenovirus type 5 injection? "H101"?, Treatment of acute cerebral infarction chemical drugs for injection Youruikelin ( "Kai Li Kang" ) and the injection of recombinant mutant human tumor necrosis factor ( "TNF") three new drugs? by the State Food and Drug Administration approval of a class of new drug certificate issued to the country, marking the real biomedical research and development group has made a major breakthrough. These three countries independently developed a class of new drugs come out, enriching the choice of domestic clinical use of drugs to enhance the welfare of the majority of patients only, while also raising the real group within the pharmaceutical industry, the continued competitiveness. Shangshiliange it as the real platform for the development of pharmaceutical industry groups, will in the future development of Chinese medicine as a whole on a real account for a significant position. Therefore, the company's future growth is self-evident.
"Youth treasure" is expected to inject the transition was determined not to change the pharmaceutical industry
The company's actual control "and the actual holding," the company's share reform program includes a commitment: to be held to its subsidiary "Hangzhou Qingchunbao" option and use the fair market price of a timely transfer or injected into the listed companies. Chia Tai Po as a youth, its Qingchunbao best-selling anti-aging tablets enduring 25 years, was hailed abroad as one of China's four national treasure, much consumers around the world, Hangzhou Zoo's giant panda Peipei on the result of long-term use Qingchunbao anti-aging film and live more than a decade, which has for the elephants. Anti-aging tablets Qingchunbao efficacy is beyond doubt. Once injected into the company, through Shangshiliange sales channels is expected to return this business Guoyi injection, will bring to the company's performance increased dramatically.
Oversold after the outbreak of
2 pole on the market, after a continuous decline in short kinetic energy has been an effective release. From the short term, the stock market on bargain-hunting has reached a volatile juncture. From long-term, the good growth in the company's future support, the stock has been severely oversold, with an excellent investment value. Investors can focus on.
